Demant stock backed by strong Q3 growth as outlook holds

Demant reported a strong third quarter on Tuesday, November 3, with group revenue up 21% year over year and organic growth of 11%. The Copenhagen-listed hearing healthcare group reiterated its 2026 outlook in an interim management statement published by Demant through Nasdaq on November 3.

Oticon Reveal drives hearing aids

Hearing aid revenue from external customers increased organically by 17% in Q3. Demant attributed the acceleration to the launch of Oticon Reveal, which strengthened the product mix and added to the momentum from Oticon Zeal.

Hearing Care delivered 6% organic growth, while Diagnostics grew 4% organically. Acquisitions, led by German hearing care retailer KIND, added to group growth and contributed to a 29% reported increase in Hearing Care revenue.

Outlook remains unchanged

Demant kept its 2026 outlook at 7% to 8% organic growth and EBIT before special items of 4.7 billion to 5.0 billion Danish kroner. The company said the forecast reflects a competitive market in which several rivals are launching products in the second half of the year.

Demant also said it expects to buy back shares worth at least 3 billion Danish kroner from the fourth quarter of 2026 through the end of 2027. A conference call on the third-quarter statement is scheduled for Wednesday, November 4, at 14:00 CET.

Business profile and positioning

Demant develops hearing aids, hearing implants, diagnostic equipment and services, and operates hearing care businesses. The group is headquartered in Denmark, serves customers in 130 countries and employs more than 26,000 people, according to the company. Its broad hearing healthcare portfolio and global distribution give it a diversified position across devices, care and diagnostics.

Investors can follow the broader market backdrop in the current market reports.

More news and analyses on Demant stock.